AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05076604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Microplegic Solution No. 1
Description: The microplegia solution that is standard of care for all cardiac surgery patients, and which all study subjects will receive is:~Induction 240 mL Baxter Cardioplegia Solution 10. 5 mL Potassium Chloride 2 meq/ml (21 meq) 250.5 mL total volume~Maintenance 747 mL Baxter Cardioplegia Solution 3.4 mL Potassium Chloride 2 meq/ml (6.75 meq) 750.4 mL total volume~Subjects will be randomly assigned to 4:1 cardioplegia or nondiluted microplegia.~4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.~Nondiluted microplegia consists of all parts human blood.
Study NCT03446378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability questionnaire will be applied
Study NCT03446378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: all patients will be submitted to a protocol of exercise with differents levels according with motor learing and neuroplasticity principles. All physical therapists were trained before the study.
Study NCT03446378 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Physical therapy
Description: all patients will be submitted to a protocol of exercise with differents levels according with motor learing and neuroplasticity principles. All physical therapists were trained before the study.
Study NCT03446378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Description: tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability questionnaire will be applied
Study NCT03446378 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability questionnaire will be applied
Study NCT05328453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal prenatal ultrasonographic evaluation.
Description: Routine fetal ultrasonography at 15-24 weeks. All sonographic measurements including 3D fetal thymus calculation was measured.
Study NCT02992860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56022473
Description: JNJ-56022473 will be supplied as a lyophilized product containing 100mg of active pharmaceutical ingredient (50 mg/mL after reconstitution with 2.0 mL sterile water for injection). The JNJ-56022473 dose administered will be dependent upon the subject's weight at baseline. The JNJ-56022473 dose should be adjusted in case the subject's weight changes by > 10%. JNJ- 56022473 will be administered in 250 mL IV infusion over approximately 180 minutes using an infusion pump.
Study NCT02992860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow analyses and CBC with differential
Description: Bone marrow analyses and CBC with differential will be performed by a central laboratory. If the marrow cannot be aspirated, a biopsy should be performed.
Study NCT02992860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flow cytometry analyses
Description: Characterization of LSCs and blasts (including CD123 and CD38 expression) will be performed as study-related analyses in the context of this protocol by central flow cytometry using bone marrow samples.
Study NCT02992860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Central biobanking
Description: Central biobanking of study samples (bone marrow, peripheral blood as well as a buccal swab) will be carried out in Dresden.
Study NCT02992860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Histopathology analysis
Description: A bone marrow biopsy is taken whenever it seems necessary to the investigator.
Study NCT02992860 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Cytogenetic analysis
Description: The cytogenetic analysis with banding analysis (optional FISH) have to be performed at local labs. Therefore 2 - 5 ml of bone marrow will be collected and analysed.
Study NCT02992860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serum chemistry
Description: For serum chemistry 15 ml (2 x 7,5 ml) of peripheral blood have to be collected.
Study NCT02992860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Automated CBC
Description: For CBC a minimum of 3 ml of peripheral blood have to be collected.
Study NCT02992860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pregnancy Test
Description: Serum or urine pregnancy testing β-HCG with a sensitivity of at least 25 mIU/mL is to be done not more than 3 days prior to initiation of JNJ-56022473 in female patients with childbearing potential. Furthermore, serum or urine pregnancy testing has to be done after end of treatment (EoT) visit.
Study NCT02360280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: sedative
Study NCT02360280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: sedative
Study NCT02360280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: sedative
Study NCT02526160 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: burosumab
Description: solution for SC injection
Study NCT02526160 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: burosumab
Description: solution for SC injection
Study NCT02526160 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline solution for SC injection
Study NCT03454087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral Dextrose Infusion
Description: A standard solution of 50% Dextrose (0.85 kcal/mL) will be infused via enteral route at a rate of 10 mL per hour for a duration of 24 hours.
Study NCT03454087 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Free Water Infusion
Description: An infusion of free water will be initiated via enteral route at a rate of 10 mL per hour for a duration of 24 hours.
Study NCT03519126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrostimulation
Description: Electrostimulation with asymmetric and depolarized biphasic current with a frequency of 10Hz and a pulse width of 200μs.
Study NCT00632125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX575 recombinant human erythropoietin alfa
Description: HX575 epoetin alfa i.v. will be administered according to the SmPC
Study NCT02801799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varying infusion rates of Ropivacaine 0.2%
Description: Participants will receive one nerve catheter adjacent to the common peroneal nerve (trial day 1) and adjacent to the sciatic nerve (trial day 2). Each catheter will be randomly allocated to one of five infusion groups. All peroneal nerve catheters will receive the same volume of ropivacaine 0.2%. All the sciatic nerve catheters will receive the same volume of ropivacaine 0.2%.~The only inter-group variable will be the infusion rate. The fixed volume of ropivacaine will be determined in a separate study ('The Volume Study'), which is also part of the project: 'A novel technique for reliable, precise and safe postoperative management'.~The largest volumes tested in The Volume Study are 30 mL for the sciatic nerve and 20 mL for the common peroneal nerve. Therefore the highest volume for the two intervention days cannot exceed 30 mL (150 mg of ropivacaine).~We will ensure constant infusion rate and precise delivery of LA by using an electronic infusion pump and a nerve catheter.
Study NCT02801799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varying infusion rates of Ropivacaine 0.2%
Description: Participants will receive one nerve catheter adjacent to the common peroneal nerve (trial day 1) and adjacent to the sciatic nerve (trial day 2). Each catheter will be randomly allocated to one of five infusion groups. All peroneal nerve catheters will receive the same volume of ropivacaine 0.2%. All the sciatic nerve catheters will receive the same volume of ropivacaine 0.2%.~The only inter-group variable will be the infusion rate. The fixed volume of ropivacaine will be determined in a separate study ('The Volume Study'), which is also part of the project: 'A novel technique for reliable, precise and safe postoperative management'.~The largest volumes tested in The Volume Study are 30 mL for the sciatic nerve and 20 mL for the common peroneal nerve. Therefore the highest volume for the two intervention days cannot exceed 30 mL (150 mg of ropivacaine).~We will ensure constant infusion rate and precise delivery of LA by using an electronic infusion pump and a nerve catheter.
Study NCT04054817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lamellar keratoplasty-ABCcolla® Collagen Ophthalmic Matrix
Description: Lamellar keratoplasty was done by removing stromal layer, ABCcolla® Collagen Ophthalmic Matrix was sutured to the defective part of the cornea.
Study NCT01075919 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: n-3 PUFAs
Description: 1 g DHA-rich fish oil taken daily for 12 weeks
Study NCT01075919 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 g olive oil taken daily for 12 weeks
Study NCT01075919 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: n-3 PUFAs
Description: 1 g EPA-rich fish oil taken daily for 12 weeks
Study NCT00626652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K201 Injection
Description: single intravenous infusion of Dose 1 - 10 or placebo (saline) or single oral capsule Dose A or placebo capsule
Study NCT00030628 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00030628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Study NCT00030628 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT
Study NCT01695382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation
Description: As per Arm description
Study NCT03784313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin repair by axillary perforator flaps
Description: Perforators flaps (PF) of the axillary region for the coverage the axillary defect left after radical excision for axillary Hidradenitis Suppurativa.~Perforated flap surgery does not involve any procedure or manipulation that may alter the biological characteristics and/or structural properties of the tissue (use autologue pur). A usual dressing is performed daily until complete healing.
Study NCT03784313 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: skin repair by secondary wound healing
Description: Secondary intention wound healing (SIWH) for the coverage the axillary defect left after radical excision for axillary Hidradenitis Suppurativa
Study NCT04575090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40 mg daily.
Study NCT01533402 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: therapist support
Description: Weekly therapist support without CBT-interventions
Study NCT01533402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT
Description: Internet-delivered cognitive behavioural therapy with therapist support
Study NCT01240499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health-At-Every-Size (HAES)
Description: 1. HAES group: 14 weekly sessions.~   Focus on general well-being and positive ways of having a healthy and satisfying lifestyle. Supported by lectures, guided self-reflection, group discussions, as well as practical exercises, this intervention aims at enhancing awareness and knowledge about biological, psychological, and sociocultural aspects of body weight.~2. SS group: 14 weekly sessions.~The objective is to reproduce a structural social support provided by the group itself. Each participant offers their support to each other. Each theme discussed in the HAES group is repeated in the SS group but the health professionals in charge of the group (dietitian \& psychologist) are not counselors (as in HAES group) but only facilitators.~Outcome measures: For all women under study.
Study NCT01240499 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health-At-Every-Size (HAES)
Description: 1. HAES group: 14 weekly sessions.~   Focus on general well-being and positive ways of having a healthy and satisfying lifestyle. Supported by lectures, guided self-reflection, group discussions, as well as practical exercises, this intervention aims at enhancing awareness and knowledge about biological, psychological, and sociocultural aspects of body weight.~2. SS group: 14 weekly sessions.~The objective is to reproduce a structural social support provided by the group itself. Each participant offers their support to each other. Each theme discussed in the HAES group is repeated in the SS group but the health professionals in charge of the group (dietitian \& psychologist) are not counselors (as in HAES group) but only facilitators.~Outcome measures: For all women under study.
Study NCT02869477 — intervention group
Intervention type: OTHER
Intervention: Data collection
Study NCT00951158 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid
Description: This is a open-label dose-titration trial of CLA in patients with advanced, refractory malignancies. The dose a participant receives is dependent upon the cohort to with the patient is assigned.~CLA will be given as oral soft gels, once daily, with pharmacokinetic sampling and biopsies (pretreatment and on day 15). Doses will be escalated by patient cohorts, using an accelerated titration design (single-patient cohorts) with expansion to conventional cohort sizes (3-6 patients) once either inhibition of S14 expression or clinical toxicity is observed. Subjects with stable or responsive disease and who tolerate treatment may continue on CLA until the time of disease progression.
Study NCT00951158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid
Description: Phase I Dose Escalation Study
Study NCT00815997 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI (percutaneous coronary intervention)
Description: PCI will be performed via the radial artery.
Study NCT00815997 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: PCI (percutaneous coronary intervention)
Description: PCI will be performed via the radial artery.
Study NCT03633253 — intervention group
Intervention type: OTHER
Intervention: Summarize of participants' characteristics using means and standard deviations or frequencies and percentages
Description: First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.
Study NCT02741648 — intervention group
Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy
Description: INVOS 5100C Cerebral/Somatic Oximeter is an FDA-approved device used to measure renal and mesenteric tissue oxygenation, as defined by regional oxygenation saturation levels (rSO2). Two probe site monitoring will be used to evaluate differential tissue bed oxygenation. Adhesive sensor probes are applied to the periumbilical area for mesenteric monitoring and to the flank area for renal monitoring.
Study NCT03943797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultivated oral mucosal epithelial cell transplantation
Description: Cultivated oral mucosal epithelial cell transplantation (COMET) will be used to treat severe limbal stem cell deficiency so as to restore the integrity of corneal surface
Study NCT00931112 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: individualized exercise training
Description: Lower extremities resistance exercise and bicycle training
Study NCT01027468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: intraocular bevacizumab injection
Study NCT01749046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remegal
Description: Remegal 1500 mg for 12 weeks
Study NCT01749046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remegal
Description: Remegal 1500 mg for 12 weeks
Study NCT04171193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: Deep anesthesia with isoflurane to achieve burst suppression pattern for more than 80% of the time for 15 minutes measured in electroencephalogram and Bi-Spectral Index
Study NCT04171193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline Pill
Description: Patients that did not respond to Isoflurane treatment, will star on sertraline to evaluate any enhancement in antidepressant efficacy after pre-treatment with isoflurane
Study NCT03235323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Counterpulsation
Description: ECP is a non-invasive method which consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading. This produces a retrograde flow of blood in the aorta resulting in a diastolic augmentation of blood flow and also an increase in venous return, which leads to an improved coronary perfusion pressure during diastole.
Study NCT02144077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BF-200 ALA
Description: Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
Study NCT02144077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyl-aminolevulinate
Description: Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
Study NCT03620149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Description: Denosumab 120 mg, SC, on day 1 of every 12-week cycle
Study NCT04135755 — intervention group
Intervention type: OTHER
Intervention: no drug intervention
Description: no drug or treatment intervention
Study NCT01345214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7746
Description: 10mg, 20mg, 50mg, 100mg, 200mg and 300mg once-daily for 14 days
Study NCT04143711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Anti-PD-1 immunotherapy agent
Study NCT04143711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: A chemotherapy treatment combining paclitaxel with albumin
Study NCT04143711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: A Trop-2 (Tumor-associated calcium signal transducer 2) directed antibody and topoisomerase inhibitor drug conjugate
Study NCT01369745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone 2.7 mg daily
Study NCT03157128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-292
Description: Oral LOXO-292
Study NCT01369745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dipyridamole
Description: dipyridamole 360 mg daily
Study NCT01369745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 5 mg daily
Study NCT01369745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z102
Description: Prednisolone 2.7 mg plus dipyridamole 360 mg daily